The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions. Specifically, the study aims to assess the treatment of Adebrelimab Injection across various subgroups of ES-SCLC patients. The goal is to provide information on treatment patterns and effectiveness in real-life settings, explore potential predictive or prognostic biomarkers, and preliminarily evaluate the pharmacoeconomic indicators of Adebrelimab Injection treatment for extensive-stage small cell lung cancer.
Voluntarily sign the informed consent form and agree to participate in the study.
Histopathologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
Age ≥ 18 years.
Determined by the investigator to be eligible for Adebrelimab treatment.
Evidence of being a pregnant or lactating female.
Currently receiving treatment as part of a blinded study protocol.
Any other condition that the investigator deems unsuitable for inclusion in the study.